The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Abstract
In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and particularly in Japan, and areas with lipiodol deposition were considered to be necrotic. However, this concept is not well accepted internationally. Furthermore, following the approval of microspheres, an embolic material that does not use lipiodol, in February 2014 in Japan, the phrase ‘lipiodol deposition' needed to be changed to ‘necrotic lesion or viable lesion'. Accordingly, the respective section in the JSH guidelines was revised to define TACE failure as an insufficient response after ≥2 consecutive TACE procedures that is evident on response evaluation computed tomography or magnetic resonance imaging after 1-3 months, even after chemotherapeutic agents have been changed and/or the feeding artery has been reanalyzed. In addition, the appearance of a higher number of lesions in the liver than that recorded at the previous TACE procedure (other than the nodule being treated) was added to the definition of TACE failure/refractoriness. Following the discussion of other issues concerning the continuous elevation of tumor markers, vascular invasion, and extrahepatic spread, descriptions similar to those in the previous version were approved. The revision of these TACE failure definitions was approved by over 85% of HCC experts. © 2014 S. Karger AG, Basel
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kudo, M., Izumi, N., Kokudo, N., Matsui, O., Sakamoto, M., Nakashima, O., Kojiro, M., Makuuchi, M., & for the HCC Expert Panel of Japan Society of Hepatology (2011) · Digestive Diseases · doi:10.1159/000327577 · Cited by 825
Self-citationKudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., Imai, Y., Okusaka, T., Miyayama, S., Tsuchiya, K., Ueshima, K., et al. (2014) · Liver Cancer · doi:10.1159/000343875 · Cited by 615
Self-citationKadalayil, L., Benini, R., Pallan, L., O'Beirne, J., Marelli, L., Yu, D., Hackshaw, A., Fox, R., Johnson, P., Burroughs, A. K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt247 · Cited by 370
Sieghart, W., Hucke, F., Pinter, M., Graziadei, I., Vogel, W., Müller, C., Heinzl, H., Trauner, M., & Peck-Radosavljevic, M. (2013) · Hepatology · doi:10.1002/hep.26256 · Cited by 343
Epidemiology and Surveillance of Hepatocellular Carcinoma
Kim, D. Y., & Han, K.-H. (2012) · Liver Cancer · doi:10.1159/000339016 · Cited by 181
How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective
Raoul, J., Gilabert, M., & Piana, G. (2014) · Liver Cancer · doi:10.1159/000343867 · Cited by 150
Kudo, M. (2012) · Liver Cancer · doi:10.1159/000342402 · Cited by 113
Self-citationChemoembolization in Patients with Hepatocellular Carcinoma
Lencioni, R. A. (2012) · Liver Cancer · doi:10.1159/000339019 · Cited by 83
Cheah, Y. L., Chow, P. K. H., Torzilli, G., Donadon, M., Cimino, M., Liapi, E., Geschwind, J.-F. H., Cha, J., Seong, J., Lin, S., et al. (2012) · Liver Cancer · doi:10.1159/000342749 · Cited by 78
Park, J., Amarapurkar, D. N., Chao, Y., Chen, P., Geschwind, J. H., Goh, K., Han, K., Kudo, M., Lee, H. C., Lee, R., et al. (2012) · Liver International · doi:10.1111/liv.12083 · Cited by 76
Self-citation
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationKudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Self-citationNew advances in the diagnosis and management of hepatocellular carcinoma
Yang, J. D., & Heimbach, J. K. (2020) · BMJ · doi:10.1136/bmj.m3544 · Cited by 384
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Kudo, M., Matsui, O., Izumi, N., Kadoya, M., Okusaka, T., Miyayama, S., Yamakado, K., Tsuchiya, K., Ueshima, K., Hiraoka, A., Ikeda, M., Ogasawara, S., Yamashita, T., Minami, T., & on behalf of the Liver Cancer Study Group of Japan
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 87
- Issue
- Suppl. 1
- Pages
- 22-31
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2068451863
- Cited by
- 283
- References
- 11
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. https://app.cochat.ai/papers/10.1159/000368142
- The paper
- Kudo, M., Matsui, O., Izumi, N., Kadoya, M., Okusaka, T., Miyayama, S., Yamakado, K., Tsuchiya, K., Ueshima, K., Hiraoka, A., Ikeda, M., Ogasawara, S., Yamashita, T., Minami, T., & on behalf of the Liver Cancer Study Group of Japan. (2014). Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update. Oncology. https://doi.org/10.1159/000368142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.